Rochal Industries, LLC — Department of Health and Human Services SBIR Phase I: 300

Rochal Industries, LLC — SBIR Phase I award from Department of Health and Human Services.

Amount
$223,944
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
300
Solicitation
PA14-071
NAICS
Place of performance
TX
Period
2015-06-01 → 2015-11-30

Description

DESCRIPTION provided by applicant There is a critical need for improved treatments for pain associated with burn injury Pain control after burn injury is a major challenge from the initial point of care through rehabilitation The overall objective of this project is to develop a easily applied topical delivery system based on analgesic microparticles that can be used for treatment of pain associated with deep partial thickness burns One of the critical barriers to progress is that current therapies are administered systemically with concomitant side effects in addition to often insufficient pain relief no topical treatments are available to treat burn pain This new topical treatment approach is designed to target pain at the source lowering usage of systemic opioids or other treatments thus reducing unwanted side effects associated with the current systemic treatments and enhancing the effectiveness of burn pain relief A key focus of this research is to determine which microparticle topical delivery system has the highest potential for burn pain relief The application of peripherally acting analgesics has been designed to provide effective simple to use easily and painlessly applied treatment of pain associated with burn injury This topical microparticle delivery technology has the potential to lead to a marketable product and the proposed technology will improve current treatment methodologies for burn injury and pain The first specific aim is to incorporate therapeutic agents into the topical delivery system The second aim is to evaluate drug release characteristics ex vivo using a bioartificial dermis system The third specific aim is to select th formulation for in vivo testing utilizing a team of clinical burn and scientific pain experts The fourth specific aim is to evaluate the efficacy of the optimized delivery system in vivo using a rodent burn model The resulting product is being designed to be a unique topical delivery system that can be used to painlessly apply analgesic treatment for burn pain The impact of this research is to help the millions of victims many of whom are children and wounded warriors who have debilitating acute and chronic pain resulting from burns PUBLIC HEALTH RELEVANCE Pain control is a major challenge from the initial point of care after burn injury through rehabilitation Burn pain is the most difficult form of acute pain to tret due to extensive tissue damage combined with the invasive nature of standard burn medical care as well as the resulting difficult chronic pain post burn closure due to peripheral neuropathy A topical treatment is critically needed to minimize the undesirable side effects associated with current systemic pain treatments and to better modulate burn pain at the source of injury